Progyny, Inc.

Equities

PGNY

US74340E1038

Managed Healthcare

Market Closed - Nasdaq 04:00:00 2024-12-06 pm EST 5-day change 1st Jan Change
14.76 USD -1.60% Intraday chart for Progyny, Inc. -5.20% -60.30%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
JPMorgan Downgrades Progyny to Neutral, Price Target is $17 Dec. 02 MT
Jefferies Adjusts Progyny Price Target to $19 From $24, Maintains Buy Rating Nov. 13 MT
Sector Update: Health Care Stocks Rise Premarket Wednesday Nov. 13 MT
Sector Update: Health Care Nov. 13 MT
Truist Downgrades Progyny to Hold From Buy, Cuts Price Target to $19 From $26 Nov. 13 MT
Progyny Q3 Adjusted Earnings, Revenue Increase; 2024 Revenue Guidance Cut Nov. 13 MT
Tranche Update on Progyny, Inc.'s Equity Buyback Plan announced on May 22, 2024. Nov. 12 CI
Tranche Update on Progyny, Inc.'s Equity Buyback Plan announced on August 6, 2024. Nov. 12 CI
Tranche Update on Progyny, Inc.'s Equity Buyback Plan announced on August 6, 2024. Nov. 12 CI
Progyny, Inc., Q3 2024 Earnings Call, Nov 12, 2024 Nov. 12
Earnings Flash (PGNY) PROGYNY Reports Q3 EPS $0.40 Nov. 12 MT
Earnings Flash (PGNY) PROGYNY Posts Q3 Revenue $286.6M Nov. 12 MT
(PGNY) PROGYNY Forecasts Q4 EPS Range $0.31 - $0.35 Nov. 12 MT
Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 Nov. 12 CI
Progyny, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 12 CI
Progyny, Inc.'s Equity Buyback announced on August 6, 2024, has closed with 5,576,767 shares, representing 6.24% for $100.2 million. Oct. 30 CI
Progyny, Inc.(NasdaqGS:PGNY) added to S&P 600 Health Care Sep. 22 CI
Progyny, Inc.(NasdaqGS:PGNY) added to S&P 600 Sep. 22 CI
Progyny, Inc.(NasdaqGS:PGNY) dropped from S&P 400 Health Care Sep. 22 CI
Progyny, Inc.(NasdaqGS:PGNY) dropped from S&P 400 Sep. 22 CI
Jefferies Cuts Price Target on Progyny to $24 From $31, Buy Rating Maintained Sep. 19 MT
Sector Update: Health Care Stocks Rise Premarket Thursday Sep. 19 MT
Wall Street Recovers From Rate Cut-Fueled Losses, Driving Premarket Gains for US Equity Futures Sep. 19 MT
Sector Update: Health Care Sep. 19 MT
Progyny's Loss of Key Client is 'Disappointing Development', Raises Concerns Over Competitiveness, Truist Says Sep. 19 MT
Chart Progyny, Inc.
PGNY: Dynamic Chart
Logo Progyny, Inc.
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Employees
565
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart PROGYNY-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
14.76USD
Average target price
18.86USD
Spread / Average Target
+27.76%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PGNY Stock
  4. News Progyny, Inc.
  5. Progyny Names Chief Commercial Officer, Chief Technology Officer